Drugs meant to reduce the risk of organ rejection may increase the risk of miscarriage and birth defects when taken by female kidney transplant patients, according to a new study. The drugs -- called ...

With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support ...

The FDA reduced its therapeutic equivalence rating in Accord Healthcare’s tacrolimus oral capsules because of safety concerns, but the generic’s approval remains, the agency said Sept. 19. Tacrolimus ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan ...